Abstract

Last year we drew attention to the confusion caused by the co-existence of coarse and fine particle preparations of griseofulvin for the treatment of fungus infections.¹ The coarse particle tablets offer no advantage and cost twice as much as the official fine particle preparation, and we concluded that they should be withdrawn. We are pleased to note that one manufacturer, ICI, has now stopped making coarse particle tablets, and is supplying only the fine particle preparation. The other manufacturer, Glaxo, will continue to supply both kinds of tablets, at least in Britain, and has introduced new labelling designed to avoid confusion between the two preparations.